The restorex_logo-h-200 technology platform is enabling cardiovascular restoration via a bioabsorbable medical device, for the first time

ETR

Endogenous Tissue Restoration (ETR) is a novel therapeutic approach, enabling the patient’s own tissue to restore complex cardiac parts within the body.

The porous structure of a Xeltis bioabsorbable device enables cardiovascular restoration once implanted. It harnesses the body’s natural healing process to pervade it with new healthy tissue and to take over functionality.

ETR in Action

Step 1

Xeltis devices work as normal heart valves or blood vessels once implanted.

Step 1
Step 2

By pervading the porous device matrix, new tissue forms around and inside the device to develop a new, healthy, functioning heart valve or blood vessel.

Step 2
Step 3

Xeltis devices are designed to absorb over time, leaving patients with a new, healthy, functioning heart valve or blood vessel.

Step 3

restorex_logo-h-200 

RestoreX is the world's first technology platform to enable cardiovascular restoration solely via implantable medical devices. Xeltis technology applies principles of Nobel Prize awarded science of supramolecular chemistry and properties of bioabsorbable polymers to cardiovascular regenerative medicine.

No in vitro tissue engineering

No stem cells

No biological agents

No animal tissue

Electrospinning
supramolecular polymers

Using electric force to draw supramolecular polymer solutions into threads that measure a fraction of the diameter of a hair.

20+ international
patent families portfolio
protecting Xeltis’ innovative supramolecular polymer platform and its electrospinning manufacturing methodology.

100,000s+ patients
with cardiovascular conditions requiring heart valve replacements and vascular interventions potentially addressed with RestoreX technology every year.

Product Pipeline

restorex_logo-h-200 Technology Outstanding 2-year clinical data at EACTS
In Vitro
Pre-Clinical
Clinical
Pulmonary Heart Valve First commercial product
In Vitro
Pre-Clinical
Clinical
Aortic Heart Valve Extending pipeline to high pressure circuit
In Vitro
Pre-Clinical
Clinical
Additional Applications Further pipeline expansion underway
In Vitro
Pre-Clinical
Clinical
In Vitro
Pre-Clinical
Clinical

Published Data

2017
30th European Association for Cardio-Thoracic Surgery (EACTS) annual meeting:
Xeltis 2-year feasibility clinical trial data of a novel bioabsorbable vascular graft in modified Fontan procedure - mid-term results View PDF
30th European Association for Cardio-Thoracic Surgery (EACTS) annual meeting:
Xeltis 1-year in vivo data of a novel bioabsorbable pulmonary heart valved conduit
96th American Association for Thoracic Surgery (AATS) annual meeting: Xeltis 1-year feasibility clinical trial data showed significant improvement in patients’ general conditions. View PDF
3rd Heart Valve Society (HVS) annual meeting: Xeltis 1-year feasibility clinical trial data show significant improvement in patients’s general conditions. View PDF
10th World Biomaterials Congress (WBC) annual meeting: Preclinical data on ETR validated potential of Xeltis technology to “guide the restoration of a patient’s natural tissue into a functional living vascular replacement.” View PDF

Nobel
Prize-Awarded Science

Jean-Marie Lehn, Nobel Laureate Awarded 1987 Nobel Prize in Chemistry for pioneering supramolecular chemistry, the science at the basis of Xeltis’ technology.
“Supramolecular chemistry enables Xeltis technology by providing unique biochemical and biomechanical properties, delivering solutions to issues faced by traditional materials over the course of decades.” Professor Lehn is a Scientific Advisor to Xeltis.
RestoreX technology platform comprises investigational devices that are not available for sale.